Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTKNASDAQ:DNLINASDAQ:ELVNNASDAQ:PRTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$34.57-3.9%$44.09$34.19▼$75.71$4.09B0.941.56 million shs3.28 million shsDNLIDenali Therapeutics$11.47-1.1%$17.35$10.57▼$33.33$1.67B1.581.07 million shs2.58 million shsELVNEnliven Therapeutics$15.82-11.5%$20.76$15.14▼$30.03$875.70M1.03282,238 shs365,172 shsPRTAProthena$10.48-3.3%$13.70$10.00▼$25.42$564.11M0.07493,764 shs746,553 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics-3.67%-10.45%-17.13%-25.81%-50.50%DNLIDenali Therapeutics-1.53%-14.71%-30.50%-45.23%-40.18%ELVNEnliven Therapeutics-4.39%-9.20%-14.90%-25.10%-7.89%PRTAProthena-0.18%-12.44%-29.01%-23.39%-53.62%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYTKCytokinetics3.8241 of 5 stars4.51.00.04.62.70.80.0DNLIDenali Therapeutics4.0625 of 5 stars4.51.00.04.73.31.70.0ELVNEnliven Therapeutics2.6154 of 5 stars3.61.00.00.03.94.20.0PRTAProthena2.6622 of 5 stars4.41.00.00.01.43.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.94Moderate Buy$82.00137.20% UpsideDNLIDenali Therapeutics 2.94Moderate Buy$37.20224.32% UpsideELVNEnliven Therapeutics 3.20Buy$38.75144.94% UpsidePRTAProthena 2.75Moderate Buy$55.00424.81% UpsideCurrent Analyst Ratings BreakdownLatest DNLI, PRTA, ELVN, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/8/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.004/4/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.003/21/2025ELVNEnliven TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$37.00 ➝ $39.003/10/2025DNLIDenali TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $28.003/7/2025CYTKCytokineticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$67.003/7/2025DNLIDenali TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$41.00 ➝ $33.003/5/2025DNLIDenali TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$38.00 ➝ $35.003/3/2025DNLIDenali TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$50.00 ➝ $42.002/28/2025CYTKCytokineticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$120.00 ➝ $120.002/28/2025DNLIDenali TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform2/28/2025DNLIDenali TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$80.00 ➝ $87.00(Data available from 4/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$18.47M221.58N/AN/A($3.94) per share-8.77DNLIDenali Therapeutics$330.53M5.04N/AN/A$7.42 per share1.55ELVNEnliven TherapeuticsN/AN/AN/AN/A$5.97 per shareN/APRTAProthena$135.16M4.17N/AN/A$10.46 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$526.24M-$5.26N/AN/AN/A-17,906.25%N/A-50.21%5/6/2025 (Estimated)DNLIDenali Therapeutics-$145.22M-$2.57N/AN/AN/AN/A-32.94%-30.04%5/6/2025 (Estimated)ELVNEnliven Therapeutics-$71.58M-$1.89N/AN/AN/AN/A-29.46%-27.33%5/13/2025 (Estimated)PRTAProthena-$147.03M-$2.30N/AN/AN/A-90.50%-22.67%-19.68%5/6/2025 (Estimated)Latest DNLI, PRTA, ELVN, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025DNLIDenali Therapeutics-$0.73N/AN/AN/A$3.24 millionN/A3/13/2025Q4 2024ELVNEnliven Therapeutics-$0.53-$0.46+$0.07-$0.46N/A$0.03 million2/27/2025Q4 2024CYTKCytokinetics-$1.29-$1.26+$0.03-$1.26$14.26 million$16.93 million2/27/2025Q4 2024DNLIDenali Therapeutics-$0.75-$0.67+$0.08-$0.67$12.75 millionN/A2/20/2025Q4 2024PRTAProthena-$1.02-$1.08-$0.06-$1.08$7.53 million$2.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AELVNEnliven TherapeuticsN/AN/AN/AN/AN/APRTAProthenaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokinetics5.939.289.28DNLIDenali TherapeuticsN/A9.989.98ELVNEnliven TherapeuticsN/A17.4417.44PRTAProthenaN/A11.5211.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/ADNLIDenali Therapeutics92.92%ELVNEnliven Therapeutics95.08%PRTAProthena97.08%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics3.40%DNLIDenali Therapeutics7.90%ELVNEnliven Therapeutics29.20%PRTAProthena28.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250118.41 million114.00 millionOptionableDNLIDenali Therapeutics430145.22 million132.55 millionOptionableELVNEnliven Therapeutics5049.00 million34.59 millionOptionablePRTAProthena13053.83 million38.64 millionOptionableDNLI, PRTA, ELVN, and CYTK HeadlinesRecent News About These CompaniesFinepoint Capital LP Grows Position in Prothena Co. plc (NASDAQ:PRTA)April 8 at 6:06 AM | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Acquired by Wellington Management Group LLPApril 7 at 4:11 AM | marketbeat.comProthena (NASDAQ:PRTA) Reaches New 12-Month Low - Here's What HappenedApril 2, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Stock Price Down 7.2% - Time to Sell?April 1, 2025 | marketbeat.comBrokers Issue Forecasts for Prothena FY2025 EarningsMarch 28, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Trading 4.8% Higher - Should You Buy?March 27, 2025 | marketbeat.comBank of New York Mellon Corp Has $2.08 Million Stake in Prothena Co. plc (NASDAQ:PRTA)March 22, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Shares Sold by Connor Clark & Lunn Investment Management Ltd.March 20, 2025 | marketbeat.comProthena Co. plc (NASDAQ:PRTA) Given Consensus Recommendation of "Moderate Buy" by AnalystsMarch 17, 2025 | marketbeat.comZacks Research Has Positive Outlook of Prothena Q1 EarningsMarch 17, 2025 | marketbeat.comZacks Research Estimates Prothena FY2027 EarningsMarch 15, 2025 | marketbeat.comProthena (NASDAQ:PRTA) Trading Down 8.1% - Should You Sell?March 12, 2025 | marketbeat.comFoundation Wealth Management LLC Makes New $270,000 Investment in Prothena Co. plc (NASDAQ:PRTA)March 8, 2025 | marketbeat.comProthena Corporation: Multiple Failures Make It RiskyMarch 3, 2025 | seekingalpha.comProthena price target raised to $110 from $94 at Piper SandlerFebruary 26, 2025 | markets.businessinsider.comProthena Reports 2024 Financial Results and 2025 OutlookFebruary 22, 2025 | tipranks.comProthena’s Balanced Earnings Call Highlights Growth and ChallengesFebruary 22, 2025 | tipranks.comAnalysts Are Bullish on These Healthcare Stocks: Prothena (PRTA), Integer Holdings (ITGR)February 22, 2025 | markets.businessinsider.comProthena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business HighlightsFebruary 21, 2025 | uk.finance.yahoo.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Insulet (PODD), Prothena (PRTA) and Travere Therapeutics (TVTX)February 21, 2025 | markets.businessinsider.comProthena price target lowered to $20 from $24 at RBC CapitalFebruary 21, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNLI, PRTA, ELVN, and CYTK Company DescriptionsCytokinetics NASDAQ:CYTK$34.57 -1.42 (-3.95%) Closing price 04:00 PM EasternExtended Trading$33.42 -1.15 (-3.33%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Denali Therapeutics NASDAQ:DNLI$11.47 -0.13 (-1.12%) Closing price 04:00 PM EasternExtended Trading$11.47 0.00 (0.00%) As of 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Enliven Therapeutics NASDAQ:ELVN$15.82 -2.05 (-11.47%) Closing price 04:00 PM EasternExtended Trading$15.82 0.00 (0.00%) As of 05:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Prothena NASDAQ:PRTA$10.48 -0.36 (-3.32%) Closing price 04:00 PM EasternExtended Trading$10.48 0.00 (0.00%) As of 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm Breaks Down But RSI Signals It’s Severely Oversold Tesla’s #1 Bull Cuts Target But Says It’s Still a Buy Will CrowdStrike's Goodwill Strategy Pay Off in Revenue Gains? Intel-Taiwan Semiconductor Alliance Fuels Turnaround Hopes Options Activity Points to More Volatility for Palantir Stock NVIDIA Stock: Oversold, Undervalued — How Low Can It Go? MicroStrategy Sees Insider Buy-Sell Action in Q1 Buffett’s Next Oil Bet: Why Occidental Is Different Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
